PitchSend

Investor Presentaiton

Investor presentation First three months of 2017 Slide 9 Increasing total market share of the basal insulin franchise in the US Weekly TRX volume market shares in the US TresibaⓇ Basal TRX MS 70% 60% 50% 40% 30% 20% 10% 0% LevemirⓇ glargine U100 NN Total Basal glargine U300 . biosimilar glargine U100 52% 31% .24% 8% 7% 4% TresibaⓇ launch in the US TresibaⓇ new to brand prescriptions market share is now 12% The uptake of TresibaⓇ was positively affected by the commercial formulary changes for CVS in the early part of the first quarter of 2017 • TresibaⓇ U200 accounts for around 75% of total TresibaⓇ volume • Wide formulary access has been obtained with around 70% access for patients in commercial channels and Medicare part D combined Note: The graph does not show NPH, which accounts for the residual market share Source: IMS weekly Xponent Plantrak (excludes Medicaid), 7 Apr 2017 TRX volume: insulin volume associated to total retail prescriptions; MS: Market share changing diabetes® Source: IMS weekly Xponent Plantrak (excludes Medicaid), 7 Apr 2017 novo nordisk

View entire presentation